Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms

References

• Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 world health organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 2015;10(9):1240–1242.
   PubMed Web of Science ®Google Scholar
• WHO Classification of Tumours Editorial Board. Thoracic tumours.5th ed. WHO classification of tumours series 5. Lyon, France: International Agency for Research on Cancer, 2021.
   Google Scholar
• Iyoda A, Makino T, Koezuka S, et al. Treatment options for patients with large cell neuroendocrine carcinoma of the lung. Gen Thorac Cardiovasc Surg. 2014;62(6):351–356.
   PubMedGoogle Scholar
• Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072.
   PubMed Web of Science ®Google Scholar
• Boyar Cetinkaya R, Aagnes B, Thiis-Evensen E, et al. Trends in incidence of neuroendocrine neoplasms in Norway: a report of 16,075 cases from 1993 through 2010. Neuroendocrinology. 2017;104(1):1–10.
   PubMed Web of Science ®Google Scholar
• Lung neuroendocrine neoplasms: recent progress and persistent challenges. Mod Pathol. 2022;35(Suppl 1):36–50.
   PubMed Web of Science ®Google Scholar
• Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an international agency for research on cancer (IARC) and world health organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–1786.
   PubMed Web of Science ®Google Scholar
• Fernandez-Cuesta L, Peifer M, Lu X, et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun. 2014;5:3518. 27
   PubMed Web of Science ®Google Scholar
• George J, Lim JS, Jang S, et al. Comprehensive genomic profiles of small cell lung cancer nature. Nature. 2015;524:47–53.
   Google Scholar
• Soldath P, Binderup T, Carstensen F, et al. Long-term outcomes after video-assisted thoracoscopic surgery in large cell neuroendocrine carcinoma. Surg Oncol. 2022;41:101728.
   PubMed Web of Science ®Google Scholar
• Baudin E, Caplin M, Garcia-Carbonero R, et al. ESMO guidelines committee. Lung and thymic carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(4):439–451.
   PubMed Web of Science ®Google Scholar
• Jawlakh H, Velikyan I, Welin S, et al. 68 Ga-DOTATOC-PET/MRI and 11 C-5-HTP-PET/MRI are superior to 68 Ga-DOTATOC-PET/CT for neuroendocrine tumour imaging. Neuroendocrinol. 2021;33:e12981. 14
   Web of Science ®Google Scholar
• Grøndahl V, Binderup T, Langer SW, et al. Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the copenhagen NET centre of excellence. Lung Cancer. 2019;132:141–149.
   PubMed Web of Science ®Google Scholar
• Lococo F, Rapicetta C, Mengoli MC, et al. Diagnostic performances of 68Ga-DOTATOC versus 18Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumours and interrelationship with histological features. Interact Cardiovasc Thorac Surg. 2019;28(6):957–960. 1
   PubMed Web of Science ®Google Scholar
• Ferolla P, Faggiano A, Mansueto G, et al. The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J Endocrinol Invest. 2008;31(3):277–286.
   PubMed Web of Science ®Google Scholar
• Zatelli MC, Torta M, Leon A, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian multicenter study. Endocr Relat Cancer. 2007;14(2):473–482.
   PubMed Web of Science ®Google Scholar
• Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol. 2004;60(5):644–652.
   PubMed Web of Science ®Google Scholar
• Yao JC, Pavel M, Phan AT, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011;96(12):3741–3749.
   PubMed Web of Science ®Google Scholar
• Oberg K, Hellman P, Ferolla P, et al. ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii120–123.
   PubMedGoogle Scholar
• Dam G, Grønbæk H, Sorbye H, et al. Prospective study of chromogranin A as a predictor of progression in patients with pancreatic, small-intestinal, and unknown primary neuroendocrine tumors. Neuroendocrinology. 2020;110(3-4):217–224.
   PubMed Web of Science ®Google Scholar
• Matar S, Malczewska A, Oberg K, et al. Blood chromogranin A Is not effective as a biomarker for diagnosis or management of bronchopulmonary neuroendocrine tumors/neoplasms. Neuroendocrinology. 2020;110(3-4):185–197.
   PubMed Web of Science ®Google Scholar
• De Jesus T, Luis SA, Ryu JH, et al. Carcinoid heart disease in patients with bronchopulmonary carcinoid. J Thorac Oncol. 2018;13(10):1602–1605. ER al
   PubMed Web of Science ®Google Scholar
• Kaltsas G, Androulakis II, de Herder WW, et al. Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer. 2010;17(3):R173–193.
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Lewis SZ, Diekemper R, et al. Executive summary: diagnosis and management of lung cancer, 3rd ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):7s–37s.
   PubMed Web of Science ®Google Scholar
• Bendixen M, Jorgensen OD, Kronborg C, et al. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. Lancet Oncol. 2016;17(6):836–844.
   PubMed Web of Science ®Google Scholar
• Falcoz PE, Puyraveau M, Thomas PA, et al. Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European society of thoracic surgeon database. Eur J Cardiothorac Surg. 2016;49(2):602–609.
   PubMed Web of Science ®Google Scholar
• Yan TD, Black D, Bannon PG, et al. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. J Clin Oncol. 2009;27(15):2553–2562.
   PubMed Web of Science ®Google Scholar
• Filosso PL, Guerrera F, Falco NR, et al. Anatomical resections are superior to wedge resections for overall survival in patients with stage 1 typical carcinoids. Eur J Cardiothorac Surg. 2019;55(2):273–279.
   PubMed Web of Science ®Google Scholar
• Saji H 1, Morihito Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;23:1607–1617.
   Google Scholar
• Detterbeck FC. Management of carcinoid tumors. Ann Thorac Surg. 2010;89(3):998–1005.
   PubMed Web of Science ®Google Scholar
• Brokx HA, Paul MA, Postmus PE, et al. Long-term follow-up after first-line bronchoscopic therapy in patients with bronchial carcinoids. Thorax. 2015;70(5):468–472.
   PubMed Web of Science ®Google Scholar
• Batchelor TJP, Rasburn NJ, Abdelnour-Berchtold E, et al. Guidelines for enhanced recovery after lung surgery: recommendations of the enhanced recovery after surgery (ERAS(R)) society and the European society of thoracic surgeons (ESTS). Eur J Cardiothorac Surg. 2019;55(1):91–115.
   PubMed Web of Science ®Google Scholar
• Oliver DE, Laborde JM, Singh DP, et al. Stephen A Rosenberg. Early-Stage primary lung neuroendocrine tumors treated with stereotactic body radiotherapy: a multi-institution experience. Int J Radiat Oncol Biol Phys. 2023;S0360-3016(23)00071-8.
   Google Scholar
• Ferolla P, Brizzi MP, Meyer T, et al. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2017;18(12):1652–1664.
   PubMed Web of Science ®Google Scholar
• Fazio N, Granberg D, Grossman A, et al. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. Chest. 2013;143(4):955–962.
   PubMed Web of Science ®Google Scholar
• Fazio N, Buzzoni R, Delle Fave G, et al. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2018;109(1):174–181.
   PubMed Web of Science ®Google Scholar
• Mariniello A, Bodei L, Tinelli C, et al. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging. 2016;43(3):441–452.
   PubMed Web of Science ®Google Scholar
• Zidan L, Iravani A, Oleinikov K, et al. Efficacy and safety of 177Lu-DOTATATE in lung neuroendocrine tumors: a bicenter study. J Nucl Med. 2022;63(2):218–225.
   PubMed Web of Science ®Google Scholar
• Zacho MD, Iversen P, Villadsen GE, et al. Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study. Scand J Gastroenterol. 2021;56(3):289–297.
   PubMed Web of Science ®Google Scholar
• Al-Toubah T, Morse B, Strosberg J. Capecitabine and temozolomide in advanced lung neuroendocrine neoplasms. Oncologist. 2020; 25(1):e48–e52.
   PubMed Web of Science ®Google Scholar
• Rewitz KS, Grønbæk H, Tabaksblat EM, et al. Prognosis of patients with bronchopulmonary neuroendocrine neoplasms in a tertiary NET centre of excellence neuroendocrinology. Neuroendocrinol. 2022;112(12):1214–1224.
   Google Scholar
• Soldath P, Binderup T, Kjær A, et al. Long-term survival and recurrence after resection of bronchopulmonary carcinoids: a single-center experience of 236 patients. Lung Cancer. 2021;156:109–116.
   PubMed Web of Science ®Google Scholar
• Fasano M, Della Corte CM, Papaccio F, et al. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol. 2015;10(8):1133–1141.
   PubMed Web of Science ®Google Scholar
• Rieber J, Schmitt J, Warth A, et al. Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas. Eur J Med Res. 2015;20(1):64.
   PubMedGoogle Scholar
• Rekhtman N, Pietanza MC, Hellmann MD, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res. 2016;22(14):3618–3629.
   PubMed Web of Science ®Google Scholar
• Metro G, Ricciuti B, Chiari R, et al. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: implications for clinical practice. Lung Cancer. 2016;95:82–87.
   PubMed Web of Science ®Google Scholar
• Derks JL, Leblay N, Thunnissen E, et al. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2018;24(1):33–42.
   PubMed Web of Science ®Google Scholar
• Miyoshi T, Umemura S, Matsumura Y, et al. Genomic profiling of large-cell neuroendocrine carcinoma of the lung. Clin Cancer Res. 2017;23(3):757–765.
   PubMed Web of Science ®Google Scholar
• Hiroshima K, Mino-Kenudson M. Update on large cell neuroendocrine carcinoma. Transl Lung Cancer Res. 2017;6(5):530–539.
   PubMed Web of Science ®Google Scholar
• Shimizu N, Akashi Y, Fujii T, et al. Use of ALK immunohistochemistry for optimal therapeutic strategy of pulmonary large-cell neuroendocrine carcinoma and identification of a novel KIF5B-ALK fusion oncokinase. Anticancer Res. 2019;39(1):413–420.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Zheng M, Jin Y, et al. ALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literature. Onco Targets Ther. 2018;11:4991–4998.
   PubMed Web of Science ®Google Scholar
• Chauhan A, Arnold SM, Kolesar J, et al. Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status. Oncotarget. 2018;9(18):14738–14740.
   PubMedGoogle Scholar
• Ohtaki Y, Kaira K, Atsumi J, et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung. Am J Transl Res. 2018;10:3243–3253.
   PubMed Web of Science ®Google Scholar